ABBV/ENTA will present the six global registrational trials as a group, which means none of these trials will be presented at 2013 AASLD. (AASLD will, however, have some phase-2 data on the 2-DAA regimen of ABT-450 + ABT-267.)
Top-line data from some of the registrational phase-3 trials will likely be announced via PR, but the companies have not yet made any commitment with respect to timing.
Market Data 
Markets 
AI
